Patents by Inventor Adonia E. Papathanassiu
Adonia E. Papathanassiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10941109Abstract: The present invention is directed to compounds and methods that inhibit the cytosolic form of BCAT1.Type: GrantFiled: August 22, 2016Date of Patent: March 9, 2021Assignee: ERGON PHARMACEUTICALS LLCInventor: Adonia E. Papathanassiu
-
Publication number: 20160368862Abstract: The present invention is directed to compounds and methods that inhibit the cytosolic form of BCAT1.Type: ApplicationFiled: August 22, 2016Publication date: December 22, 2016Applicant: Ergon Pharmaceuticals, LLCInventor: Adonia E. PAPATHANASSIU
-
Patent number: 9422224Abstract: The present invention is directed to BCAT inhibitors with the following formula: Wherein R1 is a linear alkyl group and X+ denotes a cation. These inhibitors are useful in treating autoimmune inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.Type: GrantFiled: June 12, 2012Date of Patent: August 23, 2016Assignee: ERGON PHARMACEUTICALS LLCInventor: Adonia E. Papathanassiu
-
Publication number: 20140128467Abstract: The present invention is directed to methods of using inhibitors of the cytosolic form of BCAT in the treatment of cancer, rheumatoid arthritis, and bone disease.Type: ApplicationFiled: June 12, 2012Publication date: May 8, 2014Applicant: ERGON PHARMACEUTICALS LLCInventor: Adonia E. Papathanassiu
-
Patent number: 7381799Abstract: The present invention provides a treatment for mammalian diseases characterized by pathological angiogenesis. The treatment consists of administering therapeutically active dosages of peptides containing specific amino acid sequences or antibodies that bind to cell membrane antigens on the surface of rapidly dividing endothelial cells.Type: GrantFiled: March 23, 2004Date of Patent: June 3, 2008Assignee: Ergon Pharmaceuticals LLCInventor: Adonia E. Papathanassiu
-
Patent number: 7112602Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(?)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.Type: GrantFiled: December 9, 2003Date of Patent: September 26, 2006Assignee: The Children's Medical Center CorporationInventors: Robert J. D'Amato, Shawn J. Green, John W. Madsen, William Fogler, Glenn M. Swartz, Jr., Adonia E. Papathanassiu, Jamshed H. Shah
-
Patent number: 6946439Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase inhibitors such as TFPI. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.Type: GrantFiled: February 28, 2002Date of Patent: September 20, 2005Assignee: Entre Med, Inc.Inventors: Todd Hembrough, Victor P. Pribluda, Adonia E. Papathanassiu, Shawn J. Green
-
Publication number: 20040156843Abstract: The present invention provides a treatment for mammalian diseases characterized by pathological angiogenesis. The treatment consists of administering therapeutically active dosages of peptides containing specific amino acid sequences or antibodies that bind to cell membrane antigens on the surface of rapidly dividing endothelial cells.Type: ApplicationFiled: March 23, 2004Publication date: August 12, 2004Inventor: Adonia E. Papathanassiu
-
Publication number: 20040127545Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R) (+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.Type: ApplicationFiled: December 9, 2003Publication date: July 1, 2004Applicant: Childrens' Medical CorporationInventors: Robert J. D'Amato, Shawn J. Green, John W. Madsen, William Fogler, Glenn M. Swartz, Adonia E. Papathanassiu, Jamshed H. Shah
-
Patent number: 6734163Abstract: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: GrantFiled: January 22, 2001Date of Patent: May 11, 2004Assignee: EntreMed, Inc.Inventors: Adonia E. Papathanassiu, Shawn J. Green
-
Patent number: 6673828Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.Type: GrantFiled: May 11, 1999Date of Patent: January 6, 2004Assignee: Children's Medical Center CorporationInventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Adonia E. Papathanassiu, William Fogler
-
Patent number: 6593291Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise naturally occurring, or synthetic proteins, peptides, or protein fragments capable of binding to components of the blood coagulation pathway. The compositions may be administered using a pharmaceutically acceptable carrier. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized metastasized tumors is useful for preventing the growth or expansion of such tumors.Type: GrantFiled: October 14, 1999Date of Patent: July 15, 2003Assignee: EntreMed, Inc.Inventors: Shawn J. Green, Adonia E. Papathanassiu
-
Patent number: 6528489Abstract: The present invention provides a treatment for mammalian diseases characterized by aberrant cell proliferation. The treatment consists of administering therapeutically active dosages of antibiotic inhibitors such as efrapeptin oligopeptides or mycotoxin derivatives including those comprising a-zearalenol structural motifs resulting in inhibition of cell mitosis.Type: GrantFiled: September 21, 2000Date of Patent: March 4, 2003Assignee: Ergon Pharmaceuticals LLCInventor: Adonia E. Papathanassiu
-
Publication number: 20020173465Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase inhibitors such as TFPI. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.Type: ApplicationFiled: February 28, 2002Publication date: November 21, 2002Inventors: Todd Hembrough, Victor P. Pribluda, Adonia E. Papathanassiu, Shawn J. Green
-
Publication number: 20020091081Abstract: The present invention provides a treatment for mammalian diseases characterized by pathological angiogenesis. The treatment consists of administering therapeutically active dosages of peptides containing specific amino acid sequences or antibodies that bind to cell membrane antigens on the surface of rapidly dividing endothelial cells.Type: ApplicationFiled: August 22, 2001Publication date: July 11, 2002Inventor: Adonia E. Papathanassiu
-
Publication number: 20010018204Abstract: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: ApplicationFiled: January 22, 2001Publication date: August 30, 2001Inventors: Adonia E. Papathanassiu, Shawn J. Green
-
Patent number: 5981471Abstract: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: GrantFiled: February 6, 1997Date of Patent: November 9, 1999Assignee: EntreMed, Inc.Inventors: Adonia E. Papathanassiu, Shawn J. Green